Who
Clay B. Siegall
President and CEO
Company insider
Files Form 4 as: President and CEO, Immunome; Director, Shattuck Labs; Director, Tourmaline Bio; President & CEO, Seagen; Director, Nurix Therapeutics; Director, Ultragenyx Pharmaceutical; Director, Alder Biopharmaceuticals; Director, Synlogic.
In numbers
- Trades disclosed
- 1,326
- Buys
- 12
- Sells
- 167
- Bought
- $8.3M
- Sold
- $234.2M
- Companies
- 8
- Companies where not an officer
- 6
- First trade
- 31 Jan 2006
- Last trade
- 23 Jul 2026
- Last filed
- 27 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 23 Jul 2026filed 27 Jul 2026 | IMNM ImmunomeBiotechnology | SEC FORM 4 Code A | —180,000 at $0.00 | filing |
| 23 Jul 2026filed 27 Jul 2026 | IMNM Immunomeoption or derivative · Biotechnology | SEC FORM 4 Code A | —360,000 at $0.00 | filing |
| 23 Jul 2026filed 27 Jul 2026 | IMNM Immunomeoption or derivative · Biotechnology | SEC FORM 4 Code A | —360,000 at $0.00 | filing |
| 23 Jul 2026filed 27 Jul 2026 | IMNM ImmunomeBiotechnology | SEC FORM 4 Code A | —180,000 at $0.00 | filing |
| 9 Jun 2026filed 11 Jun 2026 | STTK Shattuck LabsBiotechnology | SEC FORM 4 Bought | $250K62,500 at $4.00 | filing |
| 9 Jun 2026filed 11 Jun 2026 | STTK Shattuck LabsBiotechnology | SEC FORM 4 Bought | $250K62,500 at $4.00 | filing |
| 29 May 2026filed 2 Jun 2026 | STTK Shattuck Labsoption or derivative · Biotechnology | SEC FORM 4 Code A | —81,000 at $0.00 | filing |
| 29 May 2026filed 2 Jun 2026 | STTK Shattuck Labsoption or derivative · Biotechnology | SEC FORM 4 Code A | —81,000 at $0.00 | filing |
| 22 May 2026filed 27 May 2026 | STTK Shattuck LabsBiotechnology | SEC FORM 4 Code A | $139K128,054 at $1.08 | filing |
| 22 May 2026filed 27 May 2026 | STTK Shattuck Labsoption or derivative · Biotechnology | SEC FORM 4 Code M | —128,054 | filing |
| 22 May 2026filed 27 May 2026 | STTK Shattuck Labsoption or derivative · Biotechnology | SEC FORM 4 Code M | —128,054 | filing |
| 22 May 2026filed 27 May 2026 | STTK Shattuck LabsBiotechnology | SEC FORM 4 Code A | $138K128,054 at $1.08 | filing |
| 27 Mar 2026filed 31 Mar 2026 | IMNM ImmunomeBiotechnology | SEC FORM 4 Bought | $501K25,450 at $19.67 | filing |
| 27 Mar 2026filed 31 Mar 2026 | IMNM ImmunomeBiotechnology | SEC FORM 4 Bought | $501K25,450 at $19.67 | filing |
| 30 Dec 2025filed 30 Dec 2025 | IMNM ImmunomeBiotechnology | SEC FORM 4 Bought | $100K4,729 at $21.15 | filing |
| 19 Dec 2025filed 22 Dec 2025 | IMNM ImmunomeBiotechnology | SEC FORM 4 Bought | $149K7,278 at $20.48 | filing |
| 19 Dec 2025filed 22 Dec 2025 | IMNM ImmunomeBiotechnology | SEC FORM 4 Code G | —200,000 at $0.00 | filing |
| 18 Dec 2025filed 18 Dec 2025 | IMNM ImmunomeBiotechnology | SEC FORM 4 Bought | $1000K46,511 at $21.50 | filing |
| 28 Oct 2025filed 28 Oct 2025 | Tourmaline Biooption or derivative | SEC FORM 4 Code D | —20,000 | filing |
| 28 Oct 2025filed 28 Oct 2025 | Tourmaline Biooption or derivative | SEC FORM 4 Code D | —15,000 | filing |
The newest 500 lines are listed; the numbers count every line.
News
Arbutus Biopharma (NASDAQ:ABUS) vs. Immunome (NASDAQ:IMNM) Financial ComparisonIMNM · themarketsdaily.com · 12 Oct 2026
0 headlines in the last 90 days name Clay B. Siegall; 1 article from the last 14 days about the 2 companies they traded most, at most three about any one of them.